Altimmune Inc (ALT)

NASD · Healthcare · Biotechnology · USA

Altimmune Inc is a micro cap company (market value under $300 million) in the Biotechnology industry.

Altimmune is a biopharmaceutical company developing pemvidutide, a glucagon/GLP-1 dual receptor agonist for treating liver diseases. The company is advancing pemvidutide in clinical trials for metabolic dysfunction-associated steatohepatitis, alcohol use disorder, and alcohol-associated liver disease. Pemvidutide has demonstrated clinical benefits including liver fat reduction, weight loss, and improvements in liver inflammation markers.

From its FY2025 annual report (Form 10-K)

Intrinsic value, DCF valuation, financial health and value investing analysis for the Altimmune Inc stock.

Our verdict on ALT

Overvalued: intrinsic value $1.15 per share, market price $1.53, margin of safety -33.4% (as of 2026-11-17).

Its liquidation floor, current assets minus every liability, values the shares at $1.15; the price of $1.53 is 33% above that value.

ETFs with the most weight in ALT

17 more funds hold it; the full list is part of the paid plan.

More on ALT

Browse

Peers in Biotechnology

All 600 Biotechnology stocks

Cheaper than ALT in Biotechnology

36 more in this industry show a wider margin of safety.

Is ALT undervalued or overvalued?

ALT is overvalued (as of the 2026-11-17 close). Its liquidation floor, current assets minus every liability, values the shares at $1.15; the price of $1.53 is 33% above that value.

What is the intrinsic value of ALT?

$1.15 per share (as of the 2026-11-17 close), against a market price of $1.53. That is a margin of safety of -33.4%. The value comes from the one valuation method that applies to this company, recomputed every night after the US close.